The Journal of clinical endocrinology and metabolism · 2026
Therapeutic Plasma Exchange and Changes in Calcium, Phosphate, Parathyroid Hormone, and Fibroblast Growth Factor-23.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jin Sami SeungMi, Dugar Anushree, Hoofnagle Andrew N, Sanchez Amber P, Ward David M, Ix Joachim H, Ginsberg Charles
Аннотация
CONTEXT: Therapeutic plasma exchange (TPE) removes plasma proteins and other unwanted substances, causing nonspecific alterations of plasma components. A previous study showed an approximately 70% reduction in vitamin D metabolites following a single TPE treatment, prompting further investigation into TPE's effects on vitamin D regulators and metabolites: calcium, phosphate, parathyroid hormone (PTH), and fibroblast growth factor-23 (FGF-23).
OBJECTIVE: This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
METHODS: Measurements were taken immediately before, immediately after, and at follow-up. Paired t tests compared the percentage changes in metabolites from pre- to post-TPE.
RESULTS: Study participants (N = 42) had a mean age of 55 ± 16 years, 28 (67%) were female, and 32 (76%) were White. TPE led to acute changes in calcium (-9%; 95% CI, -11% to -8%), phosphate (-14%; -18% to -11%), and FGF-23 (-12%; -18% to -6%) concentrations. In contrast, PTH levels increased (91%; 63%-119%) from baseline to post-TPE. While most metabolites returned to baseline by the follow-up visit (median 4 [interquartile range, 3-7] days), nearly 25% of patients experienced persistent asymptomatic hypocalcemia. This persistent calcium deficit was not fully corrected by continuous intravenous calcium gluconate infusions administered during the study, nor by the endogenously increased PTH levels.
CONCLUSION: These findings underscore the need for improved care protocols and vigilant monitoring of mineral metabolism in TPE patients, especially those receiving long-term treatment. Further research is warranted to understand the enduring effects of TPE on mineral metabolism and develop strategies to prevent complications.
OBJECTIVE: This study examined changes in plasma and effluent levels of total calcium, phosphate, PTH, and FGF-23 in individuals undergoing TPE.
METHODS: Measurements were taken immediately before, immediately after, and at follow-up. Paired t tests compared the percentage changes in metabolites from pre- to post-TPE.
RESULTS: Study participants (N = 42) had a mean age of 55 ± 16 years, 28 (67%) were female, and 32 (76%) were White. TPE led to acute changes in calcium (-9%; 95% CI, -11% to -8%), phosphate (-14%; -18% to -11%), and FGF-23 (-12%; -18% to -6%) concentrations. In contrast, PTH levels increased (91%; 63%-119%) from baseline to post-TPE. While most metabolites returned to baseline by the follow-up visit (median 4 [interquartile range, 3-7] days), nearly 25% of patients experienced persistent asymptomatic hypocalcemia. This persistent calcium deficit was not fully corrected by continuous intravenous calcium gluconate infusions administered during the study, nor by the endogenously increased PTH levels.
CONCLUSION: These findings underscore the need for improved care protocols and vigilant monitoring of mineral metabolism in TPE patients, especially those receiving long-term treatment. Further research is warranted to understand the enduring effects of TPE on mineral metabolism and develop strategies to prevent complications.